Conduit Pharmaceuticals (CDTTW) Stock Price, News & Analysis

Company Overview

Conduit Pharmaceuticals Limited is a clinical-stage biopharmaceutical company focused on developing medicines for significant unmet needs in autoimmune diseases. The company uses an asset-centric business model, seeking to acquire or license promising clinical-stage drug candidates and advance them through development in collaboration with academic institutions, biotechnology companies and pharmaceutical partners.

Its pipeline has included namilumab, a monoclonal antibody designed to inhibit granulocyte-macrophage colony-stimulating factor (GM-CSF). Conduit has been evaluating namilumab in immune-mediated conditions, including sarcoidosis and other inflammatory diseases. The company’s strategy is to apply clinical and regulatory development expertise to potentially expand the use of existing therapeutic assets across additional indications.

Conduit was established in 2019 and became a publicly traded company in 2023 through a business combination with Murphy Canyon Acquisition Corp. It is based in the United Kingdom and conducts development activities through relationships with research and commercial partners. Conduit Pharmaceuticals warrants trade on Nasdaq under the symbol CDTTW.

Key Stats

• Today's Range: $0.0027 to $0.0073
• 50-Day Range: $0.0027 to $0.0129
• 52-Week Range: $0.00 to $0.02
• Volume: 30,684 shs
• Average Volume: 28,155 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CDTTW
• CIK: 1896212
• Web: www.cdtequity.com
• Phone: 760-471-8536
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A